Videos

Best Practices for Managing Patients on CDK4/6 Inhibitors

December 12th 2018

Multidisciplinary Care in Breast Cancer

December 12th 2018

Considerations for Treating Patients with CDK4/6 Inhibitors

December 12th 2018

CDK4/6 Inhibitors in Metastatic Breast Cancer

December 12th 2018

Medically Integrated Pharmacy Teams Spur Innovations

December 12th 2018

Oral Oncolytics and Patient Adherence

December 12th 2018

Medically Integrated Dispensing Service Best Practices

December 12th 2018

Practical Challenges in Switching to CDK4/6 Inhibitors

December 12th 2018

The Efficacy and Safety of CDK4/6 Inhibitors

December 12th 2018

Roles of the Oncologist Versus Pharmacist

December 12th 2018

Multidisciplinary Approach to Managing Oral Oncolytics

December 12th 2018

The Advent of Oral Oncolytics and Patient Access

December 12th 2018

Vertical Integration and Looking Toward the Future

December 11th 2018

Impact of Competition on Pricing in the Future

December 11th 2018

Factors Determining Inclusion of Biosimilars on the Formulary

December 11th 2018

Educating the Patient and Providers on Biosimilars

December 11th 2018

Role of Specialty Pharmacy Regarding Biosimilars

December 11th 2018

Challenges for Payers With Costs of Biosimilars

December 11th 2018

Pricing of Biosimilars With Biologics and Other Biosimilars

December 11th 2018

Regulatory and Legislative Impact on Biosimilars

December 11th 2018

Progress of Biosimilars and Personal Experience

December 11th 2018

Overview and Common Misunderstandings of Biosimilars

December 11th 2018

Shortage Effects on Clinical Trials and Future Hopes

December 10th 2018

Incentive Programs and Choosing a Manufacturer

December 10th 2018

Structural Overview of Supply Maintenance

December 10th 2018

The FDASIA Mandate and Interdisciplinary Communication

December 10th 2018

Palliative Fixes, Drug Essentiality, and Collateral Effects

December 10th 2018

The Risks of Drug Shortages & Timeline for Resupply

December 10th 2018

Choosing a Post-Shortage Solution and Preventive Budgeting

December 10th 2018

Unexpected Benefits and Personal Responses to Drug Shortages

December 10th 2018

Videos

Best Practices for Managing Patients on CDK4/6 Inhibitors

Multidisciplinary Care in Breast Cancer

Considerations for Treating Patients with CDK4/6 Inhibitors

CDK4/6 Inhibitors in Metastatic Breast Cancer

Medically Integrated Pharmacy Teams Spur Innovations

Oral Oncolytics and Patient Adherence

Medically Integrated Dispensing Service Best Practices

Practical Challenges in Switching to CDK4/6 Inhibitors

The Efficacy and Safety of CDK4/6 Inhibitors

Roles of the Oncologist Versus Pharmacist

Multidisciplinary Approach to Managing Oral Oncolytics

The Advent of Oral Oncolytics and Patient Access

Vertical Integration and Looking Toward the Future

Impact of Competition on Pricing in the Future

Factors Determining Inclusion of Biosimilars on the Formulary

Educating the Patient and Providers on Biosimilars

Role of Specialty Pharmacy Regarding Biosimilars

Challenges for Payers With Costs of Biosimilars

Pricing of Biosimilars With Biologics and Other Biosimilars

Regulatory and Legislative Impact on Biosimilars

Progress of Biosimilars and Personal Experience

Overview and Common Misunderstandings of Biosimilars

Shortage Effects on Clinical Trials and Future Hopes

Incentive Programs and Choosing a Manufacturer

Structural Overview of Supply Maintenance

The FDASIA Mandate and Interdisciplinary Communication

Palliative Fixes, Drug Essentiality, and Collateral Effects

The Risks of Drug Shortages & Timeline for Resupply

Choosing a Post-Shortage Solution and Preventive Budgeting

Unexpected Benefits and Personal Responses to Drug Shortages

Trending on Pharmacy Times

An Overview of the Challenges, Strategies, and Impact of Medication Adherence

Endocrine Therapy Supports Safe Radiation De-Escalation in Early-Stage Breast Cancer

FDA Approval Signals Broader Recognition of Sexual Health in Aging Women

Expert: Improving Infusion Care Through Smarter Scheduling and Analytics

FDA Approves T-DXd With Pertuzumab for First-Line Treatment of Advanced HER2+ Breast Cancer